Why is Novartis donating MDT?
Novartis developed Lamprene® (clofazimine) and Rimactane® (rifampicin), two of the three drugs used in MDT. In 1995, the WHO launched the global supply of MDT with a drug fund provided from 1995-1999 by the Nippon Foundation of Japan. From 1998 onwards, Novartis became the only supplier of high-quality MDT, the other supplier having been excluded due to sub-standard drug quality. The decision by Novartis President, Dr. Daniel Vasella, to provide MDT free of charge to all patients through the WHO was made at a critical juncture and ensured the continued availability of free treatment. This decision was a practical expression of Novartis corporate values and the belief that special efforts need to be made in tackling the diseases of poverty. Which countries are eligible for the donated drugs? Governments and government-authorized organizations involved with leprosy work only need to submit a request to the WHO in order to obtain MDT free of charge. Currently, almost 100 countries, includ
